Minakem-flap
Minakem-flap

Find Clinical Drug Pipeline Developments & Deals by Cytocom

Loading...

All Data

Filters Filter refresh
×
FILTER DATA :
Therapeutic Area filter
    Study Phase filter
      Country filter
        News Type filter
          Company filter
            refresh

            Companies By Therapeutic Area Full Screen

            Development Status Full Screen

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): CYTO-200

            Therapeutic Area: Gastroenterology Product Name: CYTO-200

            Highest Development Status: Phase II/ Phase III Product Type: Small molecule

            Partner/Sponsor/Collaborator: Cleveland Clinic

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Merger February 17, 2021

            Details:

            Combined public entity to develop and commercialize next-generation immune therapies like CYTO-200, that address unmet needs in oncology, infectious disease, inflammation and auto-immune-mediated conditions.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Naltrexone

            Therapeutic Area: Infections and Infectious Diseases Product Name: CYTO-205

            Highest Development Status: Phase II Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable February 16, 2021

            Details:

            Cytocom has submitted an Investigational New Drug (IND) application with updated protocols to the FDA to begin a Phase 2 clinical trial, to evaluate the safety and efficacy of CYTO-205 to slow or halt the progression of the SARS-CoV-2, the virus that causes COVID-19.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Noroxymorphone analogs

            Therapeutic Area: Gastroenterology Product Name: CYTO-201

            Highest Development Status: Phase II/ Phase III Product Type: Small molecule

            Partner/Sponsor/Collaborator: Cleveland BioLabs

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Merger October 20, 2020

            Details:

            Merger to create a single public company focused on the development and commercialization of immunotherapies for oncology, infectious disease, inflammation and auto-immune mediated conditions. Portfolio includes investigational drug, CYTO-201, for COVID-19 infection.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): CYTO-201

            Therapeutic Area: Infections and Infectious Diseases Product Name: CYTO-201

            Highest Development Status: Phase II Product Type: Undisclosed

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable June 29, 2020

            Details:

            Based on the FDA's feedback, Cytocom plans to revise the protocol of Company's planned Phase 2 clinical trial of CYTO-201 for the treatment of SARS-CoV-2 and quickly initiate enrollment.